| Name | Title | Contact Details |
|---|
Staffed by industry experts, Pharmatech Associates provides consulting and services to the regulated life science industry. Pharmatech`s services cover four spheres of technical expertise that are necessary throughout the complete product development lifecycle: Manufacturing—including development, Compliance, Regulatory, and Validation. Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in Asia, Europe and North America from its headquarters in the San Francisco Bay Area. Our Culture: At Pharmatech Associates, our mission is to fulfill customer expectations throughout the development and execution of tailored, high value, innovation solutions. We are committed to fostering an environment that is professional and forth right. These principles are captured in the values we believe are essential to maintaining our supportive culture and our commitment to our clients` success. We seek to establish an atmosphere of openness, objectivity, accountability, mutual respect and teamwork so each employee can realize their fullest potential for personal and professional growth. We value work life balance. At Pharmatech talent matters, and we tackle each project with a “no fear” attitude. We stand together as a team, and we`ve got your back. Pharmatech`s commitment to integrity is unwavering.
Tenami Pharmaceuticals Inc is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.
NCS PHARMACEUTICALS is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acer Therapeutics is a biotech company, headquartered in Cambridge, MA, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. Acer`s lead candidate, EDVISO™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type Ehlers-Danlos syndrome (vEDS). Ehlers-Danlos Syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. vEDS is a subtype characterized by severe arterial dissections, ruptures and early death. Complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. Median age of death is estimated to be around 50 years. Patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the COL3A1 gene. There are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the U.S. (Pepin 2014). There are no specific pharmacological treatments for vEDS and medical intervention centers on symptomatic treatment, prophylactic measures and genetic counseling. Acer was awarded orphan drug designation by the FDA in January 2015. Acer`s second candidate, ACER-001, is the first pharmaceutical therapy being developed for patients with Maple Syrup Urine Disease (MSUD). MSUD is a devastating genetic disease – an inborn error of amino acid metabolism. Approximately 800 patients suffer from MSUD in the U.S. and 3,000 worldwide. There are no therapeutic options for MSUD and diet is not enough. Despite careful dietary management, the majority of MSUD patients have chronic neurological and social impairment, as well as life-threatening episodes of intoxication. Acer was awarded orphan drug designation by the FDA in August 2014.